Protection against lethal marburg virus infection mediated by lipid encapsulated small interfering RNA

Journal of Infectious Diseases

Volumn 209, Issue 4, 2014, Pages 562-570

  Ursic Bedoya, Raul ^a   Mire, Chad E ^b,c   Robbins, Marjorie ^a   Geisbert, Joan B ^b,c   Judge, Adam ^a   MacLachlan, Ian ^a   Geisbert, Thomas W ^b,c  

^a Tekmira Pharmaceuticals Corporation   (Canada)

^b Galveston National Laboratory   (United States)

^c University of Texas Medical Branch School of Medicine   (United States)

Author keywords

filovirus; guinea pig; LNP; Marburg virus; RNAi; siRNA; therapeutics; treatment

Indexed keywords

FILOVIRUS; GUINEA PIG; LNP; MARBURG VIRUS; RNAI; SIRNA; THERAPEUTICS; TREATMENT;

ANIMALS; CARRIER PROTEINS; CYTOKINES; DRUG CARRIERS; FEMALE; GENES, VIRAL; GUINEA PIGS; LIPIDS; LIVER; MARBURG VIRUS DISEASE; MARBURGVIRUS; MICE; MICE, INBRED ICR; NANOPARTICLES; RNA, SMALL INTERFERING; SURVIVAL ANALYSIS; VIRAL LOAD;

EID: 84893263344     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit465     Document Type: Article

References (25)

1. Geisbert TW, Jahrling PB. Exotic emerging viral diseases: progress and challenges. Nat Med 2004; 10:S110-21.
2. Feldmann H, Sanchez A, Geisbert TW. Filoviridae: Marburg and Ebola viruses. In: Knipe DM, Howley PM, eds. Fields virology. 6th ed. Philadelphia: LippincottWilliams &Wilkins, 2013:923-56.
3. World Health Organization. Ebola haemorrhagic fever, Democratic Republic of the Congo. Wkly Epidemiol Rec 2012; 87:338-9.
4. World Health Organization. Ebola haemorrhagic fever, Uganda. Wkly Epidemiol Rec 2012; 87:339.
5. World Health Organization. Marburg haemorrhagic fever, Uganda. Wkly Epidemiol Rec 2012; 87:437-8.
6. Dye JM, Herbert AS, Kuehne AI, et al. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci USA 2012; 109:5034-9.
7. Warren TK, Warfield KL, Wells J, et al. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat Med 2010; 16:991-4.
8. Towner JS, Khristova ML, Sealy TK, et al. Marburg virus genomics and association with a large hemorrhagic fever outbreak in Angola. J Virol 2006; 80:6497-516.
9. Geisbert TW, Daddario-DiCaprio KM, Geisbert JB, et al. Marburg virus Angola infection of rhesus macaques: pathogenesis and treatment with recombinant nematode anticoagulant protein c2. J Infect Dis 2007; 196(suppl 2):S372-81.
10. Caplen NJ, Zheng Z, Falgout B, Morgan RA. Inhibition of viral gene expression and replication in mosquito cells by dsRNA-triggered RNA interference. Mol Ther 2002; 6:243-51.
11. Fowler T, Bamberg S, Moller P, et al. Inhibition of Marburg virus protein expression and viral release by RNA interference. J Gen Virol 2005; 86:1181-8.
12. Muller S, Gunther S. Broad-spectrum antiviral activity of small interfering RNA targeting the conserved RNA termini of Lassa virus. Antimicrob Agents Chemother 2007; 51:2215-8.
13. Artuso MC, Ellenberg PC, Scolaro LA, Damonte EB, Garcia CC. Inhibition of Junin virus replication by small interfering RNAs. Antiviral Res 2009; 84:31-7.
14. Pacca CC, Severino AA, Mondini A, et al. RNA interference inhibits yellow fever virus replication in vitro and in vivo. Virus Genes 2009; 38:224-31.
15. Geisbert TW, Hensley LE, Kagan E, et al. Postexposure protection of guinea pigs against a lethal Ebola virus challenge is conferred by RNA interference. J Infect Dis 2006; 193:1650-7.
16. Gavrilov K, Saltzman WM. Therapeutic siRNA: principles, challenges, and strategies. Yale J Biol Med 2012; 85:187-200.
17. Jeffs LB, Palmer LR, Ambegia EG, Giesbrecht C, Ewanick S, MacLachlan I. A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA. Pharm Res 2005; 22:362-72.
18. Semple SC, Akinc A, Chen J, et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 2010; 28:172-6.
19. Geisbert TW, Lee AC, Robbins M, et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 2010; 375: 1896-905.
20. Judge AD, Robbins M, Tavakoli I, et al. Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest 2009; 119:661-73.
21. Jones SM, Feldmann H, Stroher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005; 11:786-90.
22. Daddario-DiCaprio KM, Geisbert TW, Stroher U, et al. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet 2006; 367:1399-404.
23. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005; 23:457-62.
24. Robbins M, Judge A, MacLachlan I. siRNA and innate immunity. Oligonucleotides 2009; 19:89-102.
25. Ahmed F, Raghava GP. Designing of highly effective complementary and mismatch siRNAs for silencing a gene. PLoS One 2011; 6: e23443.